This is a summary of the European public assessment report (EPAR) for Sancuso. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sancuso.
Therapeutic Indication
### Therapeutic indication Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days. Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
Therapeutic Area (MeSH)
N/AATC Code
A04AA02
ATC Item
granisetron
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| granisetron | N/A | 格拉司琼 |
EMA Name
Sancuso
Medicine Name
Sancuso
Aliases
N/ANo risk management plan link.
